- $144.28m
- $131.09m
- $23.96m
- 43
- 10
- 53
- 28
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.81 | ||
| Price to Tang. Book | 7.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.71% | ||
| Return on Equity | -76.09% | ||
| Operating Margin | -93.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11.22 | 12.83 | 16.3 | 20.55 | 23.95 | 30.26 | 42.77 | 26.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Directors
- R. John Fletcher NEC (75)
- Joseph Burnett PRE (44)
- Danilo D Alessandro CFO (36)
- Peter Piferi COO (61)
- Ellisa Cholapranee GCN
- Lynnette Fallon DRC (61)
- Linda Liau DRC
- Pascal Girin IND (61)
- B. Kristine Johnson IND (69)
- Matthew Klein IND (50)
- Timothy Richards IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 12th, 1998
- Public Since
- July 3rd, 2019
- No. of Shareholders
- 230
- No. of Employees
- 107
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 27,069,568
- Address
- 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH, 92075
- Web
- https://www.clearpointneuro.com/
- Phone
- +1 9499006833
- Auditors
- Cherry Bekaert LLP
Upcoming Events for CLPT
Clearpoint Neuro Inc Annual Shareholders Meeting
Clearpoint Neuro Inc Annual Shareholders Meeting
Q2 2024 Clearpoint Neuro Inc Earnings Release
Similar to CLPT
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Clearpoint Neuro share price?
As of Today at 19:05 UTC, shares in Clearpoint Neuro are trading at $5.33. This share price information is delayed by 15 minutes.
How has the Clearpoint Neuro share price performed this year?
Shares in Clearpoint Neuro last closed at $5.33 and the price had moved by -46.59% over the past 365 days. In terms of relative price strength the Clearpoint Neuro share price has underperformed the S&P500 Index by -55.56% over the past year.
What are the analyst and broker recommendations for Clearpoint Neuro?
The overall consensus recommendation for Clearpoint Neuro is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Clearpoint Neuro dividend yield?
Clearpoint Neuro does not currently pay a dividend.
Does Clearpoint Neuro pay a dividend?
Clearpoint Neuro does not currently pay a dividend.
When does Clearpoint Neuro next pay dividends?
Clearpoint Neuro does not currently pay a dividend.
How do I buy Clearpoint Neuro shares?
To buy shares in Clearpoint Neuro you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Clearpoint Neuro?
As of the previous close price of $5.33, shares in Clearpoint Neuro had a market capitalisation of $144.28m.
Where are Clearpoint Neuro shares listed?
Here are the trading details for Clearpoint Neuro:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CLPT
What kind of share is Clearpoint Neuro?
Based on an overall assessment of its quality, value and momentum Clearpoint Neuro is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Clearpoint Neuro share price forecast for 2024?
The analyst consensus target price for shares in Clearpoint Neuro is $10.00. That is 87.62% above the last closing price of $5.33.
Analysts covering Clearpoint Neuro currently have a consensus Earnings Per Share (EPS) forecast of -$0.76 for the next financial year.
What is the trend in the Clearpoint Neuro share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clearpoint Neuro. Over the past six months, its share price has underperformed the S&P500 Index by -6.7%.
As of the last closing price of $5.33, shares in Clearpoint Neuro were trading -13.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Clearpoint Neuro PE Ratio?
The Clearpoint Neuro PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Clearpoint Neuro?
Clearpoint Neuro's management team is headed by:
- R. John Fletcher - NEC
- Joseph Burnett - PRE
- Danilo D Alessandro - CFO
- Peter Piferi - COO
- Ellisa Cholapranee - GCN
- Lynnette Fallon - DRC
- Linda Liau - DRC
- Pascal Girin - IND
- B. Kristine Johnson - IND
- Matthew Klein - IND
- Timothy Richards - IND